Potassium Chloride in Dextrose and Sodium Chloride
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP in Plastic Container VIAFLEX Plus Container
FULL PRESCRIBING INFORMATION: CONTENTS*
- POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE DESCRIPTION
- CLINICAL PHARMACOLOGY
- POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE INDICATIONS AND USAGE
- POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE CONTRAINDICATIONS
- WARNINGS
- PRECAUTIONS
- POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE ADVERSE REACTIONS
- POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL
FULL PRESCRIBING INFORMATION
POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE DESCRIPTION
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1.
| Size (mL) | Composition (g/L) |
 (calc.) |
pH | Ionic Concentration (mEq/L) |
Caloric Content (kCal/L) | |||||
| **Dextrose Hydrous, USP | Sodium Chloride, USP (NaCl) | Potassium Chloride, USP (KCl) | Sodium | Potassium | Chloride | |||||
| Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection, USP | ||||||||||
| mEq Potassium | ||||||||||
| 10 mEq | 1000 | 50 | 2 | 0.75 | 341 | 4.5 (3.5 to 6.5) |
34 | 10 | 44 | 170 |
| 20 mEq 10 mEq |
1000 500 |
50 | 2 | 1.5 | 361 | 4.5 (3.5 to 6.5) |
34 | 20 | 54 | 170 |
| 30 mEq | 1000 | 50 | 2 | 2.24 | 381 | 4.5 (3.5 to 6.5) |
34 | 30 | 64 | 170 |
| 40 mEq | 1000 | 50 | 2 | 3 | 401 | 4.5 (3.5 to 6.5) |
34 | 40 | 74 | 170 |
| Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection, USP | ||||||||||
| mEq Potassium | ||||||||||
| 20 mEq 10 mEq |
1000 500 |
50 | 3.3 | 1.5 | 405 | 4.5 (3.5 to 6.5) |
56 | 20 | 76 | 170 |
| 30 mEq | 1000 | 50 | 3.3 | 2.24 | 425 | 4.5 (3.5 to 6.5) |
56 | 30 | 86 | 170 |
| 40 mEq | 1000 | 50 | 3.3 | 3 | 446 | 4.5 (3.5 to 6.5) |
56 | 40 | 96 | 170 |
| Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP | ||||||||||
| mEq Potassium | ||||||||||
| 10 mEq | 1000 | 50 | 4.5 | 0.75 | 426 | 4.5 (3.5 to 6.5) |
77 | 10 | 87 | 170 |
| 20 mEq 10 mEq |
1000 500 |
50 | 4.5 | 1.5 | 447 | 4.5 (3.5 to 6.5) |
77 | 20 | 97 | 170 |
| 30 mEq | 1000 | 50 | 4.5 | 2.24 | 466 | 4.5 (3.5 to 6.5) |
77 | 30 | 107 | 170 |
| 40 mEq | 1000 | 50 | 4.5 | 3 | 487 | 4.5 (3.5 to 6.5) |
77 | 40 | 117 | 170 |
| Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection, USP | ||||||||||
| mEq Potassium | ||||||||||
| 20 mEq | 1000 | 50 | 9 | 1.5 | 601 | 4.5 (3.5 to 6.5) |
154 | 20 | 174 | 170 |
| 40 mEq | 1000 | 50 | 9 | 3 | 641 | 4.5 (3.5 to 6.5) |
154 | 40 | 194 | 170 |
The VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
CLINICAL PHARMACOLOGY
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP has value as a source of water, electrolytes and calories. It is capable of inducing diuresis depending on the clinical condition of the patient.
POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE INDICATIONS AND USAGE
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP is indicated as a source of water, electrolytes and calories.
POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE CONTRAINDICATIONS
Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.
WARNINGS
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention. Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.
Injections containing carbohydrates with low electrolyte concentration should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis. The container label for these injections bears the statement: Do not administer simultaneously with blood.
The intravenous administration of Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.
In patients with diminished renal function, administration of Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP may result in sodium or potassium retention.
In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
Potassium salts should never be administered by IV push.
PRECAUTIONS
Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.
Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Caution must be exercised in the administration of Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP should be used with caution in patients with overt or subclinical diabetes mellitus.
The osmolarity of Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP ranges from 341 to 641 mOsmol/L (calc). Administration of hypertonic solutions may cause venous irritation, including phlebitis. Hyperosmolar solutions should be administered with caution, if at all, to patients with hyperosmolar states.
Carcinogenesis, mutagenesis, impairment of fertility
Studies with Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
Pregnancy
Teratogenic Effects
Pregnancy Category C.
Animal reproduction studies have not been conducted with Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP. It is also not known whether Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP should be given to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP is administered to a nursing mother.
For patients receiving potassium supplement at greater than maintenance rates, frequent monitoring of serum potassium levels and serial EKGs are recommended.
Do not administer unless solution is clear and seal is intact.
Pediatric Use
The use of Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP in pediatric patients is based on clinical practice.
Newborns – especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitits, bronchopulmonary dysplasia, prolonged length of hospital stay, and death.
Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.
The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in hyponatremia in patients with acute volume depletion. Hyponatremia can lead to headache, nausea, seizures, lethargy, coma, cerebral edema and death, therefore acute symptomatic hyponatremic encephalopathy is considered a medical emergency (applies to solutions containing less than 0.9% Sodium Chloride Injection).
Geriatric Use
Clinical studies of Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE ADVERSE REACTIONS
- Hypersensitivity reactions, including anaphylaxis and chills
- Hyponatremia (applies to solutions containing less than 0.9% Sodium Chloride)
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE DOSAGE AND ADMINISTRATION
As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.
All injections in VIAFLEX Plus plastic containers are intended for intravenous administration using sterile equipment.
The dosage selection and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
HOW SUPPLIED
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP in VIAFLEX Plus plastic container is available as follows:
| Code | Size (mL) | NDC | Product Name |
| 2B1604 | 1000 | 0338-0661-04 | 10 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection, USP |
| 2B1614 2B1613 |
1000 500 |
0338-0663-04 0338-0663-03 |
20 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection, USP |
| 2B1624 | 1000 | 0338-0665-04 | 30 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection, USP |
| 2B1634 | 1000 | 0338-0667-04 | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection, USP |
| 2B1474 2B1473 |
1000 500 |
0338-0603-04 0338-0603-03 |
20 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection, USP |
| 2B1484 | 1000 | 0338-0605-04 | 30 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection, USP |
| 2B1494 | 1000 | 0338-0607-04 | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection, USP |
| 2B1644 | 1000 | 0338-0669-04 | 10 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP |
| 2B1654 2B1653 |
1000 500 |
0338-0671-04 0338-0671-03 |
20 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP |
| 2B1664 | 1000 | 0338-0673-04 | 30 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP |
| 2B1674 | 1000 | 0338-0675-04 | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP |
| 2B2434 | 1000 | 0338-0803-04 | 20 mEq/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection, USP |
| 2B2454 | 1000 | 0338-0807-04 | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection, USP |
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.
DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
For Information on Risk of Air Embolism – see Precautions
To Open
Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.
Preparation for Administration
- Suspend container from eyelet support.
- Remove protector from outlet port at bottom of container.
- Attach administration set. Refer to complete directions accompanying set.
To Add Medication
Warning: Additives may be incompatible.
To add medication before solution administration
- Prepare medication site.
- Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
- Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
To add medication during solution administration
- Close clamp on the set.
- Prepare medication site.
- Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
- Remove container from IV pole and/or turn to an upright position.
- Evacuate both ports by squeezing them while container is in the upright position.
- Mix solution and medication thoroughly.
- Return container to in use position and continue administration.
Baxter Healthcare Corporation
Deerfield, IL 60015 USA
Printed in USA
Distributed in Canada by
Baxter Corporation
Mississauga, ON L5N 0C2
*For Bar Code Position Only
071969877
07-19-69-877
Rev. Sept 2013
Baxter, PL 146, and Viaflex are trademarks of
Baxter International Inc.
PACKAGE LABEL - PRINCIPAL DISPLAY PANEL
LOT
EXP
2B1604
NDC 0338-0661-04
DIN 00786225
10 mEq
Potassium
Chloride
(10 mEq/L)
Potassium Chloride in 5% Dextrose and
0.2% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
200 mg SODIUM CHLORIDE USP 75 mg POTASSIUM CHLORIDE USP
pH 4.5 (3.5 TO 6.5) mEq/L SODIUM 34 POTASSIUM 10 CHLORIDE
44 OSMOLARITY 341 mOsmol/L (CALC) STERILE NONPYROGENIC
SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE CONSULT
WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE
ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE
INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS
CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT BE USED
IN SERIES CONNECTIONS DO NOT ADMINISTER SIMULTANEOUSLY WITH BLOOD DO NOT USE UNLESS SOLUTION IS CLEAR Rx ONLY STORE UNIT
IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F)
UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
FOR PRODUCT INFORMATION
1-800-933-0303
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1604X
14-1000 ML
VIAFLEX PLUS CONTAINER
10 mEq POTASSIUM CHLORIDE IN 5% DEX
AND 0.2% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380661041
LOT
EXP
2B1614
NDC 0338-0663-04
DIN 00503142
20 mEq
Potassium
Chloride
(10 mEq/L)
Potassium Chloride in 5% Dextrose and
0.2% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
200 mg SODIUM CHLORIDE USP 150 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 34 POTASSIUM 20 CHLORIDE 54
OSMOLARITY 361 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT ADMINISTER
SIMULTANEOUSLY WITH BLOOD DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION 1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1614X
14-1000 ML
VIAFLEX(R) PLUS CONTAINER
20 MEQ POTASSIUM CHLORIDE IN 5% DEX
AND 0.2% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380663045
2B1624
NDC 0338-0665-04
DIN 00786233
30 mEq
Potassium
Chloride
(30 mEq/L)
Potassium Chloride in 5% Dextrose and
0.2% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
224 mg POTASSIUM CHLORIDE USP 200 mg SODIUM CHLORIDE USP
pH 4.5 (3.5 TO 6.5) mEq/L SODIUM 34 POTASSIUM 30 CHLORIDE
64 OSMOLARITY 381 mOsmol/L (CALC) STERILE NONPYROGENIC
SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE CONSULT
WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE
ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE
INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS
CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT BE USED
IN SERIES CONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR
FEDERAL (USA) LAW PROHIBITS DISPENSING WITHOUT A PRESCRIPTION
STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT
VIAFLEX® PLUS CONTAINER
PL 146® PLASTIC
FOR PRODUCT INFORMATION
1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1624X
14-1000 ML
VIAFLEX PLUS CONTAINER
30 mEq POTASSIUM CHLORIDE IN
5% DEX AND 0.2% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380665049
2B1634
NDC 0338-0667-04
DIN 00503150
40 mEq
Potassium
Chloride
(40 mEq/L)
Potassium Chloride in 5% Dextrose and
0.2% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
300 mg POTASSIUM CHLORIDE USP 200 mg SODIUM CHLORIDE USP
pH 4.5 (3.5 TO 6.5) mEq/L POTASSIUM 40 SODIUM 34 CHLORIDE
74 HYPERTONIC OSMOLARITY 401 mOsmol/L (CALC) STERILE NONPYROGENIC
SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE
CONSULT WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE
INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS
CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT BE USED
IN SERIES CONNECTION S DO NOT USE UNLESS SOLUTION IS CLEAR Rx ONLY
STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
FOR PRODUCT INFORMATION
1-800-933-0303
Baxter VIAFLEX and
PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1634X
14-1000 ML
VIAFLEX® PLUS CONTAINER
40 MEQ POTASSIUM CHLORIDE IN 5% DEX
AND 0.2% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380667043
LOT
EXP
2B1473
NDC 0338-0603-03
DIN 00786241
10 mEq
Potassium
Chloride
(20 mEq/L)
Potassium Chloride in 5% Dextrose and
0.33% Sodium Chloride Injection USP
500 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
330 mg SODIUM CHLORIDE USP 150 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 56 POTASSIUM 20 CHLORIDE 76
HYPERTONIC OSMOLARITY 405 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION 1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1473Q
24-500 ML
VIAFLEX PLUS CONTAINER
10 MEQ POTASSIUM CHLORIDE IN
5% DEX AND 0.33% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380603034
LOT
EXP
2B1484
NDC 0338-0605-04
DIN 00786268
30 mEq
Potassium
Chloride
(30 mEq/L)
Potassium Chloride in 5% Dextrose and
0.33% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
330 mg SODIUM CHLORIDE USP 224 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 56 POTASSIUM 30 CHLORIDE 86
HYPERTONIC OSMOLARITY 425 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR FEDERAL (USA) LAW PROHIBITS
DISPENSING WITHOUT PRESCRIPTION STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX® PLUS CONTAINER
PL 146® PLASTIC
FOR PRODUCT INFORMATION
CALL 1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1484
12 - 1000 ML
VIAFLEX PLUS CONTAINER
30 mEq POTASSIUM CHLORIDE IN
5% DEX AND 0.33% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380605045
LOT
EXP
2B1494
NDC 0338-0607-04
DIN 00786276
40 mEq
Potassium
Chloride
(40 mEq/L)
Potassium Chloride in 5% Dextrose and
0.33% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
330 mg SODIUM CHLORIDE USP 300 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 56 POTASSIUM 40 CHLORIDE 96
HYPERTONIC OSMOLARITY 446 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR FEDERAL (USA) LAW PROHIBITS
DISPENSING WITHOUT PRESCRIPTION STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX® PLUS CONTAINER
PL 146® PLASTIC
FOR PRODUCT INFORMATION
CALL 1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1494
12 - 1000 ML
VIAFLEX PLUS CONTAINER
40 mEq POTASSIUM CHLORIDE IN
5% DEX AND 0.33% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380607049
LOT
EXP
2B1644
NDC 0338-0669-04
DIN 00790109
10 mEq
Potassium
Chloride
(10 mEq/L)
Potassium Chloride in 5% Dextrose and
0.45% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
450 mg SODIUM CHLORIDE USP 75 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 77 POTASSIUM 10 CHLORIDE 87
HYPERTONIC OSMOLARITY 426 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION 1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1644X
14-1000 ML
VIAFLEX(R) PLUS CONTAINER
10 MEQ POTASSIUM CHLORIDE IN 5% DEX
AND 0.45% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380669047
2B1653
NDC 0338-0671-03
DIN 00437999
10 mEq
Potassium
Chloride
(20 mEq/L)
Potassium Chloride in 5% Dextrose and
0.33% Sodium Chloride Injection USP
500 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
450 mg SODIUM CHLORIDE USP 150 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 77 POTASSIUM 20 CHLORIDE 97
HYPERTONIC OSMOLARITY 447 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
FOR PRODUCT INFORMATION
1-800-933-0303
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1653Q
24-500 ML
VIAFLEX PLUS CONTAINER
10 MEQ POTASSIUM CHLORIDE IN
5% DEX AND 0.45% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380671033
LOT
EXP
2B1664
NDC 0338-0673-04
DIN 00786284
30 mEq
Potassium
Chloride
(30 mEq/L)
Potassium Chloride in 5% Dextrose and
0.45% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
450 mg SODIUM CHLORIDE USP 224 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 77 POTASSIUM 30 CHLORIDE 107
HYPERTONIC OSMOLARITY 466 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION
1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1664X
14-1000 ML
VIAFLEX(R) PLUS CONTAINER
30 MEQ POTASSIUM CHLORIDE IN 5% DEX
AND 0.45% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380673044
LOT
EXP
2B1674
NDC 0338-0675-04
DIN 00438006
40 mEq
Potassium
Chloride
(40 mEq/L)
Potassium Chloride in 5% Dextrose and
0.45% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
450 mg SODIUM CHLORIDE USP 300 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 77 POTASSIUM 40 CHLORIDE 117
HYPERTONIC OSMOLARITY 487 mOsmol/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION
1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B1674X
14-1000 ML
VIAFLEX(R) PLUS CONTAINER
40 MEQ POTASSIUM CHLORIDE IN 5% DEX
AND 0.45% SODIUM CHLORIDE INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) XXXXX (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380675048
LOT
EXP
2B2434
NDC 0338-0803-04
DIN 00786292
20 mEq
Potassium
Chloride
(20 mEq/L)
Potassium Chloride in 5% Dextrose and
0.9% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
900 mg SODIUM CHLORIDE USP 150 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 154 POTASSIUM 20 CHLORIDE 174
OSMOLARITY 601 mOsmol/L (CALC) HYPERTONIC
MAY CAUSE VEIN DAMAGE STERILE NONPYROGENIC
SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE
CONSULT WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY
DO NOT STORE DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE
AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT
BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS
SOLUTION IS CLEAR Rx ONLY STORE UNIT IN
MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION
1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B2434X
14-1000 ML
VIAFLEX(R) PLUS CONTAINER
20 MEQ POTASSIUM CHLORIDE IN
5% DEX AND 0.9% SOD CHL INJ, USP
EXP
XXXXX
SECONDARY BAR CODE
(17) XXXXX (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380803045
LOT
EXP
2B2454
NDC 0338-0807-04
DIN 00786306
40 mEq
Potassium
Chloride
(40 mEq/L)
Potassium Chloride in 5% Dextrose and
0.9% Sodium Chloride Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
900 mg SODIUM CHLORIDE USP 300 mg POTASSIUM
CHLORIDE USP pH 4.5 (3.5 TO 6.5) mEq/L
SODIUM 154 POTASSIUM 40 CHLORIDE 194
OSMOLARITY 641 mOsmol/L (CALC) HYPERTONIC MAY CAUSE VEIN
DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINER
ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST
IF AVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC
TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE
INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS
CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT
STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT BE USED IN SERIES
CONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR Rx ONLY
STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE
(25°C/77°F) UNTIL READY TO USE AVOID EXCESSIVE HEAT
SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION
1-800-933-0303
Baxter logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA
2B2454X
14-1000 ML
VIAFLEX(R) PLUS CONTAINER
40 MEQ POTASSIUM CHLORIDE IN
5% DEX AND 0.9% SODIUM CHLORIDE INJ
EXP
XXXXX
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
LOT
XXXXX
PRIMARY BAR CODE
(01) 50303380807043
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium Chloride in Dextrose and Sodium ChloridePotassium Chloride, Dextrose Monohydrate and Sodium Chloride INJECTION, SOLUTION
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
